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Abstract
Background: Tumor necrosis factor-alpha (TNF-a) is a pro-inflammatory cytokine today identified as a key mediator of
several chronic inflammatory diseases. TNF-a, initially synthesized as a membrane-anchored precursor (pro-TNF-a), is
processed by proteolytic cleavage to generate the secreted mature form. TNF-a converting enzyme (TACE) is currently the
first and single protease described as responsible for the inducible release of soluble TNF-a.
Methodology/Principal Findings: Here, we demonstrated the presence on THP-1 cells as on human monocytes of a
constitutive proteolytical activity able to cleave pro-TNF-a. Revelation of the cell surface TACE protein expression confirmed
that the observed catalytic activity is due to TACE. However, further studies using effective and innovative TNF-a inhibitors,
as well as a highly selective TACE inhibitor, support the presence of a catalytically different sheddase activity on LPS
activated THP-1 cells. It appears that this catalytically different TACE protease activity might have a significant contribution
to TNF-a release in LPS activated THP-1 cells, by contrast to human monocytes where the TACE activity remains catalytically
unchanged even after LPS activation.
Conclusions/Significance: On the surface of LPS activated THP-1 cells we identified a releasing TNF-a activity, catalytically
different from the sheddase activity observed on human monocytes from healthy donors. This catalytically-modified TACE
activity is different from the constitutive shedding activity and appears only upon stimulation by LPS.
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Introduction
Tumor Necrosis Factor-a (TNF-a) is a pro-inflammatory
cytokine produced and secreted primarily by macrophages and
monocytes in response to a bacterial challenge or tumor burden.
Tumor Necrosis Factor-a plays a key role in host defense and
immunosurveillance. Overproduction and secretion of TNF-a
may have detrimental effects and are strongly involved in acute
inflammation, in chronic inflammatory diseases, and probably also
in several cancer types initiation (e.g. colorectal cancer compli-
cating colonic inflammatory bowel diseases).
Large amounts of TNF-a are released in response to
lipopolysaccharide (LPS) and other bacterial products (e.g.
staphylococcal enterotoxin B, bacterial super antigen toxin 1).
However, several other agents can also modulate its expression
including other cytokines such as interleukin 1 and 2 (IL-1 and IL-
2), TNF-a itself, cross-linking FccR, granulocyte-monocyte
colony-stimulating-factor (GM-CSF), macrophage colony-stimu-
lating-factor (M-CSF), CD40 ligand, glucocorticoids and phorbol
esters [1,2,3,4]. It is well established that the induction of TNF-a
production upon stimulation by LPS results from both an
enhancement of TNF-a gene transcription and a translational
derepression of its mRNA. In non-stimulated macrophages, TNF-
a m-RNA translation is blocked. Upon activation by LPS this
repression is overcome. The newly synthesized TNF-a protein
initially accumulates primarily within the Golgi complex and then
goes through the secretory pathway up to the cell surface [3]. The
TNF-a is transported from the trans-Golgi network (TGN) in
tubular carriers/vesicles to the recycling endosome (RE), which
serve as an intermediary compartment before cell surface delivery
[5].
A transient appearance of TNF-a on the cell plasma membrane
is followed by degradation/endocytosis [6] or by proteolytical
cleavage of the full length TNF-a transmembrane protein (pro-
TNF-a or m-TNF-a) to release a soluble mature form (s-TNF-a)
[7]. This process called ‘‘ectodomain shedding’’ remains a critical
point regulating TNF-a secretion and function, providing a strong
incentive to define the responsible sheddases and to understand
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the underlying proteolytic machinery. Previous studies demon-
strated that pro-TNF-a can be processed by a membrane
associated serine protease or metalloprotease, and that metallo-
protease inhibitors can effectively inhibit the release of s-TNF-a
[8,9,10]. Up to now, only one enzyme - TACE/ADAM17 (Tumor
Necrosis Factor Converting Enzyme, EC 3.4.24.86) - has been
found to specifically cleave pro-TNF-a [11,12], despite the
constitutive shedding of TNF-a seems not to be managed only
by TACE [13,14,15,16,17]. Beside TACE, several other ADAMs
have been implicated in TNF-a shedding, i.e. ADAM10, most
closely related to TACE [18,19], as well as ADAMs 9 and 19
[17,20]. Whilst ADAM10 and TACE can cleave a peptide
mimicking the physiological cleavage site of TNF-a, in exactly the
same position that in cells (SPLAQA76-V77RSSSR), the others
(ADAM9 and 19) do not match the physiologically relevant site
(cleavage sites are: SPLA-QAVRSSSR for ADAM 9 and
SPLAQAVRS-SSR and SPLAQAVR-SSSR for ADAM19).
Other enzymes have been considered to be implicated as well in
TNF-a shedding, including MMP7/matrilysin [21] and serine
protease PR3 (cleavage site: SPLAQAV-RSSSR) [7,9]. Taking all
together, there is some evidence for multiple sheddase activities
being involved in the cleavage of TNF-a. Nevertheless, the
mechanism of in vivo regulation of shedding activity is not yet well
understood. One can hypothesize that these activities may differ
depending on several factors such as cell types, constitutive or
induction conditions and acute or chronic inflammatory condi-
tions. Therefore, this work was designed to provide a better
understanding of the molecular phenomenon’s associated with
TNF-a release from secreting cells. For this purpose, we used three
original TNF-a secretion inhibitors: Thymoquinone (TQ), Celas-
trol and Ro 32-7315. Thymoquinone and Celastrol are synthetic
molecules derived from plants. Thymoquinone is the main active
constituent of the volatile oil of Nigella sativa black seeds [22],
whereas Celastrol is a dienone-phenolic triterpen isolated from
Tripterygium wilfordii [23]. Both compounds have been previously
described as potent anti-oxidant, and anti-inflammatory mole-
cules, able to inhibit TNF-a production [24,25,26]. Ro 32-7315
was developed by ROCHE as a potent, orally active TACE
inhibitor, based on succinate hydroxamate scaffold, which reached
phase I clinical trials [27,28]. Ro 32-7315 displays 100–500-fold
selectivity over MMPs-1,-2,-3,-9,-13 but not for MMP-8 [29,30].
Results
The specific TACE inhibitor Ro 32-7315, TQ and Celastrol
confirmed a high potency to inhibit TNF-a secretion
Ro 32-7315, TQ and Celastrol have been selected here as well
characterized anti-TNF-a compounds. First we aimed to assess
their anti-TNF-a potency in our cell-based inflammation models:
human mononuclear cells isolated from peripheral blood
(PBMCs), human monocytes purified from peripheral blood
(PBMs) and the human monocytic cell line (THP-1). In order to
obtain a TNF-a secretion mimicking tissue inflammatory activa-
tion, cells were activated by lipopolysaccharide (LPS), a major
inducer of TNF-a (production and release). The LPS dose
respectively used for each cell type (PBMC 5 mg/ml; THP-1
1 mg/ml) is issued from a ‘‘data not shown’’ dose response.
Inhibition of LPS induced TNF-a release by Ro 32-7315, TQ and
Celastrol, was measured for different concentrations. As illustrated
in Figure 1a, Ro 32-7315 induced a dose dependent inhibition of
TNF-a release and this for all the 3 tested cell types.
Concentrations lower than 10 mM were sufficient to obtain a
complete inhibition of cytokine secretion. In a similar way, both
TQ and Celastrol inhibited TNF-a secretion in a dose-dependent
manner and were able to completely block its secretion (Figure 1b
and 1c). In our hands, Celastrol presented the best anti-TNF-a
activity, much better than the specific TACE inhibitor, Ro 32-
7315.
In the range of tested concentrations, cell viability was not
affected for all tested compounds (data not shown), confirming that
the observed effects were due to their anti-TNF-a activity and not
to cell death. Their strong potency to block TNF-a release is
highlighted by their low IC50 values as shown in Table 1.
TNF-a accumulation onto cell surface after specific TACE
inhibition
TNF-a is initially synthesized as a transmembrane precursor (m-
TNF-a), then processed by TACE and/or other sheddase to
become a secreted soluble form. Blocking of this process e.g. by
TACE inhibitors should thus generate TNF-a retention and
accumulation on the cellular membrane. To verify the cogency of
our hypothesis, we evaluated m-TNF-a expression in cells
pretreated by Ro 32-7315, a specific TACE inhibitor. As
demonstrated by flow cytometry (Figure 2 panel A and Figure 3),
Ro 32-7315 treatment yielded in an important accumulation of m-
TNF-a. The obtained MFI (AU) values for THP-1 cells and
PBMC were 260 vs. 64 (p= 0.049) and 90 vs. 30 (p= 0.046)
(treated vs. control cells), respectively. We further performed
confocal microscopy in order to validate the membrane localiza-
tion of retained TNF-a after TACE inhibitor treatment. As shown
in Figure 4, a strong cell surface staining was visible in the
presence of Ro 32-7315 in both THP-1 and monocytes.
Visualization of membrane anchored TNF-a revealed a punctu-
ated distribution at the cell surface, suggesting a lipid raft
localization of TNF-a. Tellier et al. have shown that the mature
form of TNF-a is mainly present in the cholesterol-rich membrane
microdomains (lipid rafts) and that an inhibition of metallopro-
teases increases the proportion of TNF-a in those parts [31]. Thus
our results confirm that inhibiting TACE activity leads to an
accumulation of unprocessed TNF-a on the cell surface.
Thymoquinone and Celastrol induce an accumulation of
cell surface m-TNF-a
As for Ro 32-7315, we demonstrated that TQ and Celastrol, are
both able to produce a substantial increase in the m-TNF-a
expression (Figure 2 panel A and B and Figure 3). The MFI (AU)
values obtained for those agents were: 635 vs 64 (THP-1 cells;
p = 0.049) and 81 vs 30 (PBMC; p= 0.046) for TQ; 663 vs 86
(THP-1; p= 0.049) and 170 vs 30 (PBMC; p= 0.049) for Celastrol.
The observed properties of TQ and Celastrol to strongly inhibit
TNF-a secretion together with important capacity to retain
uncleaved TNF-a on the cell surface indicate that both are able
to block m-TNF-a processing strongly suggesting an anti-TACE
activity.
Cell surface TACE expression on THP-1 cells and PBMCs
To provide evidence for TACE expression on THP-1 cells as
well as on PBMCs, we performed flow cytometry analysis of LPS-
activated and non-activated cells (Figure 5). Both THP-1 and
PBMC resting cells demonstrated a cell surface TACE expression
with MFI values (AU) of 270 and 300 respectively, compared to 70
(p = 0.049) and 66 (p= 0.049) for unstained cells. Treatment of the
THP-1 cells and PBMC by LPS for 4 or 24 hours respectively,
corresponding to the maximum release of soluble TNF-a secretion
accordingly to each cell type, did not change significantly the levels
of TACE protein expression (MFI values: 290 AU for THP-1 cells
and 320 AU for PBMC, p= 0.657), indicating that TACE
THP-1 TACE Catalytically Different from Monocyte
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expression in both cell types does not depend from LPS
stimulation. These data are consistent with those described in
the literature, where no increase in the amount of surface TACE
has been found in response to various cell activators [32].
Moreover, Doedens and Black demonstrated that LPS stimulation
of THP-1 cells has no effect on TACE localization or expression
suggesting that the basal level of TACE activity may be sufficient
for the release of TNF-a from LPS stimulated monocytic cells.
Figure 1. Inhibition of TNF-a secretion by different human cell types in presence of Ro 32-7315, TQ and Celastrol. Cells (56105/ml)
were incubated for 4 hours (for human monocytes and THP-1 cells) or 24 hours (for PBMC) with 1or 5 mg/ml LPS respectively, in the presence of
ranging compounds concentrations or 0.1% (v/v) DMSO as a control. The TNF-a levels were then assessed in culture supernatant by ELISA technique.
Dose-response curves were fitted on GraphPad PRISM (v.4.0, GraphPad Software, Inc. La Jolla, CA,USA) sigmoidal dose-response curve-fit model (n = 3
independent experiments); s-TNF-a correspond to the secreted form of TNF-a. Statistical difference between IC50 of Ro 32-7315, TQ and Celastrol are
indicated in Table 1.
doi:10.1371/journal.pone.0034184.g001
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Thus the effect of LPS may be solely to induce neo-synthesis of
TNF-a, which is then released after constitutive TACE activity
[33]. Another explanation, suggested by Li et al., could be that
TACE molecular structure changes or is degraded after TNF-a
secretion [14].
THP-1 cells and PBMs surface associated enzymatic
activity
After having shown the presence of TACE, we analyzed in a
next step TACE enzymatic activities present on THP-1 cells and
PBMs. For this purpose a highly sensitive fluorometric assay based
on fluorescence-quenched (FRET) peptides as substrates was used.
This method permitted a continuous real-time monitoring of the
enzyme activity on the surface of living cells. Two FRET
substrates have been considered of interest: i) the first is MOCA,
a broad-spectrum MMP substrate, particularly sensitive for testing
collagenase (MMP-1, -8, 13), TACE and ADAM 10, ii) the second
is ABZ, a highly TACE specific substrate.
Intact THP-1 cells, as PBMs, were found able to hydrolyze each
peptide, indicating the presence of constitutive enzymatic activities
on the cell surface (data not shown).
By using Ro 32-7315 on PBMs we noticed that this specific
TACE inhibitor caused significant inhibition of TACE-specific
ABZ hydrolysis (almost 80%) and only a slight inhibition of
MOCA hydrolysis (Figure 6). In contrast, TQ did not display any
effect on TACE-specific ABZ hydrolysis on PBMs, while Celastrol
induced moderate inhibition ,25%) (Figure 6). However, both
TQ and Celastrol displayed inhibitory activities on MOCA
hydrolysis by PBMs (respectively ,35% and 50%). These results
were supported by those obtained in THP-1 cells, showing a
significant inhibition of the MOCA hydrolysis with only minimal
inhibition of ABZ hydrolysis by TQ and Celastrol (Figure 7).
However, Ro 32-7315 developed as a selective TACE inhibitor,
surprisingly blocked significantly the cleavage of MOCA but only
minimally ABZ, the TACE specific substrate (Figure 7). These
observations indicate that THP-1 cells exhibit a different
enzymatic activity able to process m-TNF-a in physiological
conditions. Despite it seems that both TQ and Celastrol are able to
target this different TACE enzymatic activity, Celastrol is also able
to block the genuine TACE. In addition, Ro 32-7315 presented
some capacity to inhibit this activity, suggesting a protein structure
similarity for both activities as previously illustrated by cell surface
specific anti-TACE antibody recognition on the two cell types
(figure 5).
Recombinant human TACE activity inhibition study
In order to validate the results of a differential enzymatic
activity obtained with our cell-based fluorogenic peptide cleavage
assays, human recombinant TACE was used to directly measure
the effects of TQ and Celastrol on enzyme activity. Our data
confirmed the strong anti-TACE potential of Ro 32-7315
(Figure 8). As formerly stated, Celastrol was able to inhibit TACE,
however only at high concentrations. For TQ we obtained only a
discrete rhTACE activity inhibition, even for the highest
concentrations, so that the inhibition profile we obtained appears
comparable to the one obtained for human monocytes when tested
with the TACE specific ABZ substrate (see Figure 7 and 8).
However, it is important to consider that in these latter
experiments on a soluble rhTACE protein, one main actor was
missing i.e. the influence of the cell membrane composition.
Discussion
While inhibition of TNF-a secretion by Ro 32-7315 is
attributed to blockade of TACE catalytic activity, there are no
such reports for other biologically active and potentially clinically-
attractive molecules (or their derivatives) such as Celastrol or TQ.
It is well documented that anti-TNF-a activity of both Celastrol
and TQ results principally directly from their inhibitory activity on
NF-kB, a transcription factor strongly involved in induction of
TNF-a production [25,26,34]. In order to study whether Celastrol
and TQ could, as Ro 32-7315, influence TACE catalytic activity,
we performed flow cytometry analysis of membrane-anchored
TNF-a expression. When secretion of TNF-a increases, TNF-a on
the cell surface decreases, in particular during LPS stimulation so
that the presence of specific proteases inhibitors prevents TNF-a
release from the cell membrane, potentially resulting in its
retention and accumulation on cell surface. However, other
authors such as Gearing et al., reported that TNF-a secretion
inhibition by metalloproteinase inhibitors does not result in
membrane-bound TNF-a accumulation on in vitro human
leukocytes cultures [10]. Additionally, Decoster et al. demonstrated
that non-secretable, biologically active mutant of m-TNF-a
expressed in L929 cells did not reveal an increased numbers of
TNF-a molecules on the cell membrane, despite the fact that these
molecules are not longer cleaved. The proposed explanation was
that a homeostatic feedback mechanism conducted to an m-TNF-
a rapid recycling and degradation inside the cells [35]. In
opposition to previous authors, Shurety et al. showed that the
metalloprotease inhibitor BB-3103 known to inhibit TACE, causes
retention of m-TNF-a on LPS-stimulated RAW264 cells and this
for relatively long periods, up to 16 hours [6]. In our hands and in
accordance with Shutery et al. report, the selective TACE
inhibitor Ro 32-7315 significantly increased the number of cells
bearing high m-TNF-a levels in LPS activated THP-1 cells as well
as in PBMC. In the absence of any TACE inhibitor, an increase in
surface-associated TNF-a could not be observed after LPS
activation, even when cells were treated by Rolipram, a non-
protease inhibitor of TNF-a secretion (data not shown). These
observations strongly indicate that a rapid processing and release
Table 1. IC50 (mM) values of tested compounds for TNF-a
release by human monocytes, THP-1 cells and PBMC (n = 3
independent experiments) are estimated using GraphPad
PRISMH 5.0 d (GraphPad Software, Inc., San Diego CA).
Compounds IC50 (nM)
THP-1A MonocytesB PBMCC
Ro 32-7315 2906132 360648 24006175
Thymoquinone 740061885 40006192 22006174
Celastrol 90622 0.4660.1 44617
The half-maximal inhibition values (IC50) for each tested compounds is
determined by fitting the data to the sigmoid dose-response equation:
Y~Bottomz(Top{Bottom)=(1z10 ^ ((logIC50{X )))
where X is the logarithm of the compound’s concentration, Y is the TNF-a
release. Bottom the baseline response and Top is the maximum response.
Statistical significances: (A) IC50’s in THP-1 are significantly different between
the 3 compounds; p = 0.027 (Kruskal-Wallis). As a result we could compare each
compound individually to the two others (Mann Whitney): Ro-32-7315 vs.
Thymoquinone, p = 0.049; Ro-32-7315 vs. Celastrol, p = 0.049; Thymoquinone vs.
Celastrol, p = 0.049; (B) same statistical significances in monocytes than in THP-1
cells A. (C) p = 0,039 for PBMC (Kruskall-Wallis); Ro-32-7315 vs. Thymoquinone,
p.0.05 (not significant); Ro-32-7315 vs. Celastrol, p = 0.049; Thymoquinone vs.
Celastrol, p = 0.049.
doi:10.1371/journal.pone.0034184.t001
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of TNF-a to the extracellular compartment appears following LPS
stimulation, and that a TACE inhibitor can effectively prevent this
event resulting in a membrane anchored TNF-a accumulation. To
support this concept, we provide confocal microscopic pictures
showing a strong cell surface immuno-reactivity after Ro 32-7315
treatment in both THP-1 cells and human monocytes. Visualiza-
tion of membrane-anchored TNF-a reveals its punctuated
distribution at cell surface, either cells are being or not treated
by TACE inhibitors. The characteristics of this distribution
strongly suggest an association with the cholesterol-rich membrane
micro-domains (lipid rafts) localization of m-TNF-a, and might
play an important role in TNF-a secretion. In fact, recent finding
demonstrated that TNF-a mature form is present in this cell
membrane compartment and that inhibition of metalloproteases
increases TNF-a proportion in those parts of the cell [31]. In
addition we demonstrated the presence of TACE on both cell
types, THP-1 and PBMCs, confirming that the observed TNF-a
retention can really be attributed to TACE inhibition. While in
our hands Celastrol and TQ showed to produce an important m-
TNF-a increase expression in PBMC and THP-1 cells after LPS
stimulation, well correlated with a significant decrease in s-TNF-a,
we could suggest that both compounds are able to block TACE
shedding activity. Subsequently, we studied TACE catalytic
activity developing a cell-based fluorimetric assay of real time
monitoring of enzymatic activity. The assay is based on
fluorescence-quenched peptides as a substrate encompassing the
cleavage sequence of TNF-a as recognized by TACE. Enzymatic
hydrolysis of the peptide leads to an increase in fluorescence
intensity, proportional to the amount of cleaved peptide. First we
used the broad-spectrum MMP substrate (MOCAc-Lys-Pro-Leu-
Gly-Leu-Dap(Dnp)-Alz-Arg-NH2, MOCA), particularly sensitive
for collagenase (MMP-1,-8,-13) and TACE, and in a lesser extend
for ADAM10. Although this substrate is not based exactly on a
pro-TNF-a amino acid sequence, Neumann et al. reported its
kcat/Km value as much higher than those of the standard TACE
substrates mimicking the physiological cleavage site of TNF-a
[36]. TACE does not possess strict crucial specificity for the A-V
scissile bond cleaving efficiently the others [37]. Thus, strengthen
by good water solubility, use of this substrate in our shedding
assays allowed us a sensitive detection of TACE activities on in situ
cell surfaces. Results obtained with the MOCA substrate were
then compared with those obtained with a second, this time highly
specific, TACE substrate: Abz-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-
Ser-Arg-Dap(Dnp)-NH2 (ABZ) [37]. This latter is based on the
amino-acid sequence strictly identical to the scissile region of the
genuine pro-TNF-a allowing a highly specific determination of
TACE shedding activity. Hydrolysis study of MOCA and ABZ
substrates by non-activated THP-1 cells and human monocytes
showed that both cell types are able to cleave each substrate (data
not shown), clearly indicating the presence of a constitutive
enzymatic activity on the cells surface explaining this result. In
addition, we showed that TACE expression on both cell types is
independent on LPS stimulation, suggesting a constitutive level of
TACE activity sufficient for TNF-a release. This is consistent with
the findings of Doedens et al. reporting that THP-1 cells LPS
stimulation has no effect on TACE localization and expression
[33]. One of the possible explanations of this observation may be
that LPS first induces TNF-a synthesis before regulating
constitutive TACE activity [33] (suggesting that the molecular
structure of TACE could be changed or degraded [14]). However,
it should be taken into consideration, that TACE surface
expression might not be an adequate indicator of its cellular
activity, especially that a TACE-mediated ectodomain shedding
may occur in an intracellular compartment in addition to the cell
surface. Furthermore, it has also been shown that TACE is
predominantly localized at a perinuclear compartment similar to
that described for TNF-a [38]. To date there is no report about
the proportion of shedding occurring at the cell surface compared
to intracellular compartments. However, noting that the mem-
brane-anchored protein form of TACE represents the majority of
its mature form, it can be suggested that at least the majority of the
shedding takes place on cell surface. Studying further the effects of
the tested potential TACE inhibitors on MOCA and ABZ
hydrolysis by both THP-1 cells and human monocytes, we showed
that Ro 32-7315, Celastrol and TQ all induced a significant
reduction of MOCA peptide hydrolysis by THP-1 cells, although
none of the inhibitors were able to completely abrogate the
MOCA cleavage. Surprisingly, none of them were able to strongly
inhibit ABZ hydrolysis as obtained for MOCA. Using such a
highly specific TACE substrate (ABZ) and a highly selective
TACE inhibitor (Ro 32-7315) we expected to gain complete
abrogation of ABZ hydrolysis, indeed we obtained only 20%
abrogation. Consequently, the fact that about 80% of constitutive
TACE activity remains unchanged after Ro 32-7315 treatment,
might suggest that in physiological conditions, TACE could occur
in a conformational different state then following LPS activation,
less accessible to this inhibitor. A similar consideration can be
hypothesized for Celastrol and TQ, inhibiting hydrolysis of ABZ
substrate for about 40% (Celastrol) or 20% (TQ) and MOCA
substrate for about 85% or 58%, respectively. In support came our
observations on human monocytes. In these cells, Ro 32-7315
induced almost 80% ABZ hydrolysis inhibition, and this with only
a little inhibition of MOCA hydrolysis, confirming its high anti-
TACE potential. For Celastrol and TQ we obtained a similar
profile in THP-1 cells, although the capacity of both compounds
to inhibit MOCA and ABZ substratehydrolysis was much less
pronounced. These results indicate that unlike Ro 32-7315,
Celastrol and TQ trigger a better TACE inhibition on activated
THP-1 cells. To amplify our findings, we studied the effects of all
three compounds on human recombinant TACE activity. As
expected, our results for rhTACE confirm a strong inhibi-
tory potency of Ro 32-7315. Celastrol, but not TQ, can also
efficiently inhibit TACE activity, however only at much higher
concentrations.
In summary we demonstrate here that:
– cell surface TACE protein is present on THP-1 and PBMC in
a rate independent of cellular activation,
– Ro 32-7315, Celastrol and TQ inhibit TACE activity as
illustrated by important increase in m-TNF-a expression as
well as real time monitoring of enzymatic activity,
– independently of the cell type, THP-1 or monocyte, as for
recombinant TACE protein, hydrolysis of the broad-spectrum
MMP substrate MOCA is inhibited more or less but in an
Figure 2. THP-1 cell surface accumulation of membrane-bound TNF-a after Ro 32-7315 and TQ (Panel A) or Celastrol (Panel B)
treatment. Cells were stimulated for 4 hours (1 mg/ml of LPS) in the presence of Ro 32-7315 (3.5 mM), TQ (10 mM) and Celastrol (10 mM) or 0.1% (v/v)
DMSO as a control. The intact cells were then stained by FITC-anti-m-TNF-a MAb. Membrane-bound TNF-a expression was evaluated in flow
cytometry. Representative histograms are shown. The fluorescence intensity (AU) is plotted versus the number of cells. For all 3 compounds,
membrane –bound TNF-a expression increased after THP-1 cells were treated (p,0.05).
doi:10.1371/journal.pone.0034184.g002
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equivalent manner respectively by Ro 32-7315, Celastrol and
TQ.
– on the contrary, hydrolysis of the highly specific TACE
substrate Abz if strongly inhibited by Ro 32-7315 on monocyte,
for THP-1 cells only a 20% inhibition is obtained.
Our data suggest that in human THP-1 cells, TACE activity is
catalytically changed after LPS activation, compared to human
monocytes where TACE appears less sensitive to the presence or
stimulation by LPS as shown by the differential inhibitory activities
of Ro 32-7315, Celastrol or TQ. Thus the THP-1 cell line might
not be a good cell line to screen chemical libraries in the quest of
new TACE inhibitors.
Materials and Methods
Reagents and compounds
Biotin mouse anti-human TNF-a antibody, purified anti-human
TNF-a (capture) antibody, recombinant humanTNF-a and
CellFIXH were purchased from BD Biosciences Pharmingen (Le
Pont de Claix, France). Phosphate buffer saline (PBS) Dulbecco
w/o Ca2+, Mg2+ (PBS Instamed) was from Biochrom AG (VWR,
Fontenay-sous-Bois, France). Fetal Bovin Serum (FBS) was
obtained from Lonza BioWhittaker (Fisher Bioblock Scientific,
Illkirch, France). Brj 35 detergent, 30% aqueous solution was from
Calbiochem/Merck (VWR, Fontenay-sous-Bois, France). Penicil-
lin-streptomycin was purchased from Cambrex Bio Science (St
Beauzire, France). 96 wells culture plates was from Corning
International (Avon, France). L-glutamine was obtained from
GIBCO (Invitrogen, Cergy Pontoise, France). 24-wells tissue
culture treated plates, 25 and 75 cm2 polystyrene sterile flask,
Figure 3. PBMC surface accumulation of the membrane-bound
TNF-a after Ro 32-7315, Celastrol and TQ treatment. Cells were
stimulated for 24 hours with 5 mg/ml of LPS in the presence of 10 mM of
Ro 32-7315, TQ and Celastrol. 0.1% (v/v) DMSO was used as a control
(silver histogram). The non-permeabilized cells were then stained with
FITC-anti-m-TNF-a MAb. Membrane TNF-a expression was evaluated by
flow cytometry. The representative histograms are shown. The
fluorescence intensity (AU) is plotted against the number of cells (y-
axis). For all 3 compounds, membrane–bound TNF-a expression
increased after THP-1 cells were treated (p,0.05, n = 3).
doi:10.1371/journal.pone.0034184.g003
Figure 4. Immunofluorescence of membrane-bound TNF-a on
the surface of THP-1 cells and human monocytes after Ro 32-
7315 treatment. Cells were stimulated for 4 hours with LPS (1 mg/ml)
in the presence of Ro 32-7315. Then, cells were stained by FITC-anti-m-
TNF-a MAb. Image acquisition was made on a confocal microscope. The
numerical recording of the images and analysis were carried out in
Image J (Wayne Rasband, National Institute of Mental Health, Bethesda,
Maryland, USA.).
doi:10.1371/journal.pone.0034184.g004
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and15 or 50 ml polypropylene tube were from Greiner bio-one
(Courtaboeuf, France). Guava Nexin Assay kit, Guava ViaCount
kit and 7-AAD were purchased from Guava Technologies (CA,
USA). Tris(hydroxymethyl)-aminomethan was from Merck (Lyon,
France). 1,4 ml U-tubes and Nunc maxisorp plates were from
Micronic (Dominique Dutscher, Brumath, France). FRET sub-
strates: Abz-Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Ser-Arg-
Dap(Dnp)-NH2) and MOCAc-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-
Ala-Arg-NH2 were purchased from Peptides International (Louis-
ville, KY, USA). Monoclonal anti-human extracellular TNF-a-
Fluorescein, monoclonal anti-human TACE-Phycoerythrin and
Human recombinant TACE were obtained from R&D Systems
Europe (Lille, France). Dimethyl Sulfoxide (DMSO), Hank’s
balanced salt solution (HBSS), Histopaque-1077, Lipopolisacchar-
ide (LPS) from Salmonella abortus equi, RPMI 1640, SigmaFast
OPD (O-phenylenediamine dihydrochloride), Thimerosal (Mer-
cury-[(o-carboxyphenyl)thio]ethyl sodium salt), Tween 20 and
Zinc chloride ZnCl2 were obtained through Sigma-Aldrich (Saint-
Quentin Fallavier, France). VectashieldH Hard SetTM was from
Vector Laboratories (CliniSciences, Montrouge, France). Strepta-
vidin-Horseradish peroxidase (HRP) was from Zymed (Clinis-
ciences, Montrouge, France). Ro 32-7315 was a generous gift of
Dr. Keith Walker (Roche, Palo Alto, CA USA), as Celastrol by Pr.
AC Allison (Alavita Pharmaceuticals, Mountain View, CA USA).
Cells, cell cultures and cells incubations
The human monocytic cell line THP-1 (from the American
Type Culture Collection, ATCC) was routinely maintained in
RPMI 1640 culture medium supplemented with 10% (v/v) heat
inactivated FBS and penicilin-streptomycin (100 IU/ml and 1 mg/
ml).
The human peripheral blood monocytes, purchased at the
‘‘Etablissement Franc¸ais du Sang-Alsace’’ (EFS, Strasbourg,
France), were a generous gift of Professor Sylvie Fournel
(Immunologie et Chimie The´rapeutiques UPR 9021 CNRS,
IBMC, Strasbourg, France). The cells were obtained by elutriation
from healthy donors with no clinical history. The used cell
suspension (in RPMI 1640 culture medium supplemented with
10% (v/v) heat inactivated FBS and penicilin-streptomycin
(100 IU/ml and 1 mg/ml)) contained 70% of monocytes and
10% of granulocytes.
For human blood mononuclear cells (PBMC) studies, healthy
donors with no clinical history were selected. Written consent from
each donor was obtained following the recommendations of the
‘‘Comite´ de Protection des Personnes (CPP) Nord Ouest II’’ which
gave his agreement the 12/07/2006 followed by the agreement of
the ‘‘Direction Ge´ne´rale de la Sante´’’ the 01/21/2007 (protocol
#2006-A00319-42), and the work carried out according to
international guidelines.
Figure 5. TACE expression on surface of THP-1 Cells and
PBMCs. Non-activated or LPS stimulated cells (4 hours by 1 mg/ml of
LPS for THP-1 cells or 24 hours by 5 mg/ml of LPS for PBMC) were
stained with Phycoerythrin labelled anti-TACE MAb. Cell surface TACE
expression was then evaluated by flow cytometric analysis. The
ordinate relates to the relevant cell number, while fluorescence
intensity can bee seen on the abscissa, representing cell surface TACE
level. Silver histogram show unstained cells. Green and red lines present
stained cells, non-activated and activated, respectively. Difference is
statistically significant (p = 0.049 for both THP-1 and PBMC, n = 3).
doi:10.1371/journal.pone.0034184.g005
Figure 6. Effects of Ro 32-7315, Celastrol and TQ on MOCA and
ABZ substrates hydrolysis by human monocytes as compared
to the THP-1 cell line (inset). The enzymatic activity was determined
for viable intact cells using MOCA and ABZ substrates (n = 3). Thus,
0.56106/ml of viable cells were incubated with 5 mM of the substrate in
Ca2+ and Mg2+ free HBSS in the presence of compounds (10 mM).
Fluorescence intensity was monitored for 600 s, and the rates of the
peptide hydrolysis were then calculated from the linear section of
the fluorescence curve. The inhibitory potency of the compounds was
calculated by divining the reaction rates of substrate hydrolysis obtain-
ed for different compounds concentrations (V(substrate)[inhibitor])
by substrate hydrolysis reaction rate with DMSO addition
(V(substrate)[0.1% DMSO]). Inhibitory potency (%) = 100%2
(V(substrate)[inhibitor]/V(substrate)[0.1% DMSO])6100%.
doi:10.1371/journal.pone.0034184.g006
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PBMCs were separated in a single-step density centrifugation
technique, as previously described [39]. Briefly, peripheral blood
diluted in Ca2+ and Mg2+ free (CMF) HBSS (CMF-HBSS) was
layered over Histopaque-1077 and centrifuged for 30 minutes at
400 g (20uC). Cells harvested from the interface were washed 3
times in CMF-HBSS and re-suspended in a culture medium
consisting in RPMI 1640 supplemented with 10% (v/v) heat
inactivated FBS and penicillin-streptomycin (100 IU/ml and
1 mg/ml). THP-1 cells and human monocytes were incubated in
96 wells culture plates for 4 hours, human PBMCs for 24 hours, at
37uC in a humidified 5%CO2/95% air atmosphere in presence of
increasing doses of the tested compounds. The final concentration
of cells was 56105/ml in a final volume of 250 ml per well.
Lipopolysaccharide (LPS) from Salmonella abortus equi was used to
induce TNF-a secretion by cells (1 mg/ml for THP-1 cells and
human monocytes and 5 mg/ml for PBMCs). Optimal LPS (from
Salmonella abortus equi) concentrations have been established in
previous experiments as optimal LPS concentrations vary from
one bacterial species origin to another, and differ also considering
the studies which would be performed (data not shown).
Compounds, dissolved in DMSO, were diluted in culture medium
and added to the cells cultures with a DMSO final concentration
never exceeding 0.1% (v/v). Control samples always contained the
same amount of DMSO (without drug) to exclude any interference
of DMSO in cell responses.
After the incubation period, the supernatants were removed and
stored at 220uC prior to ELISA assay.
Compound’s toxicity measurements
The Guava Nexin Assay was used for discriminating viable,
necrotic and apoptotic cells by the means of Annexin V-PE and 7-
AAD labeling. Annexin V-PE detects phosphatidylserin (PS) on
external membrane of early and late stage apoptotic cells, whereas
7-AAD, a non permeant dye, detects late stage apoptotic cells and
Figure 7. Effects of Ro 32-7315, Celastrol and TQ on MOCA and
ABZ substrates hydrolysis by THP-1 cells. The viable intact THP-1
cells (0.56106 cells/ml) were incubated with 5 mM of the MOCA or ABZ
substrate in Ca2+ and Mg2+ free HBSS in the presence of various
concentrations of Ro 32-7315, Celastrol or TQ. The final DMSO
concentration in the reaction mixture was 0.1%. The fluorescence intensity
was monitored for 600 s and the rates of the substrates hydrolysis were
calculated from the linear section of the fluorescence curve. To estimate
the accurate inhibitory potency of the tested compounds, the reaction
rates of MOCA hydrolysis obtained for different compounds concentra-
tions (V(MOCA)[inhibitor]) were divided by MOCA hydrolysis reaction rate
in the presence of 0.1%DMSO (V(MOCA)[0.1% DMSO]). Inhibitory potency
(%)= 100%2(V(MOCA)[inhibitor]/V(MOCA)[0.1% DMSO])6100%.
doi:10.1371/journal.pone.0034184.g007
Figure 8. Effects of Ro 32-7315, Celastrol and TQ on rh TACE
activity. 100 ng/ml of rh TACE were incubated with 5 mM of MOCA
substrate in 25 mM Tris, pH 9.0, 2.5 mM ZnCl2, 0.005% Brij 35, in the
presence of different compounds concentrations. The compounds were
injected directly into the reaction solution every 600 s and the fluorescence
intensity was monitored at l excitation/l emission: 325/400 nm, at room
temperature. To estimate the accurate inhibitory potency of the tested
compounds, the reaction rates of MOCA hydrolysis obtained for different
compounds concentrations (V(MOCA)[inhibitor]) were divided by MOCA
hydrolysis reaction rate with DMSO addition (V(MOCA)[DMSO]). Inhibitory
potency (%)=100%2(V(MOCA)[inhibitor]/V(MOCA)[DMSO])6100%.
doi:10.1371/journal.pone.0034184.g008
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dead cells. Prior to the Guava Nexin assay, LPS activated PBMC
or THP-1 cells were incubated in 96 wells culture plates for
24 hours and 4 hours respectively, at 37uC in humidified 5% CO2
(95% air atmosphere) in the presence or absence of the tested
compounds. The supernatants were then removed and the cells
were resuspended in 200 ml of fresh culture medium and stained
with 20 ml of Annexin V-PE and 7-AAD mixture (1/1 V/V in
fresh culture medium). After 20 minutes of incubation (in the dark
at room temperature) the samples were analyzed on the Guava
EasyCyte Plus System (Guava Technologies) equipped with a
488 nm excitation laser and four emission filters at 520/40, 585/
42, 675/30 and 780/30 nm. The samples were analyzed using
Guava ExpressH Plus software. Granulation, size and fluorescence
intensity were recorded for 5,000 cells.
Soluble TNF-a detection and quantification by ELISA
Quantitative evaluation of secreted TNF-a in culture superna-
tants was achieved by a two-site Enzyme-Linked Immunosorbent
Assay (ELISA), as previously described [40]. Polyvinyl chloride
plates were coated with 100 ml per well of purified anti-human
TNF-a capture antibodies (2 mg/ml) and incubated overnight at
4uC. After washing and saturation steps, 50 ml of standard or
samples were added to 50 ml of biotinylated monoclonal antibody
(1 mg/ml) for 2 hours at room temperature. Following washing
steps, 100 ml of a peroxidase streptavidin dilution (1/2000 in PBS)
were added (45 minutes at room temperature). A colorimetric
reaction using 0-phenylenediamine dihydrochloride (OPD) as
peroxidase substrate was performed ensuing three washing steps.
The optical density (OD) of each well was determined at 450 nm
using Versamax microplate reader linked to the SoftMax Pro
software (Molecular Devices). TNF-a concentrations (pg/ml)
of unknown samples were computed by interpolation with a
standard curve run on each plate using four parameters logistics
analysis.
Immunofluorescence staining for membrane bound TNF-
a and TACE detection
The cells to be stained were incubated in 24 wells culture plate
for 4 hours (for THP-1 cells and monocytes) or 24 hours (PBMC),
at 37uC in humidified 5% CO2 (95% air atmosphere). The final
cellular concentration was 56105 cells/ml for 1 ml per well. The
cells were activated with LPS: 1 mg/ml for THP-1 cells and
monocytes or 5 mg/ml for PBMC. For TNF-a detection cells were
incubated in the presence of the tested compounds or 0.1%
DMSO (control samples).
Following incubation period, the cells were harvested and
washed in CMF-HBSS supplemented with 0.5% FBS. Prior to
staining, cells were Fc-blocked by treatment with 1 mg of human
IgG for 15 minutes at room temperature. Each sample was then
placed on ice and finally incubated 30 minutes with monoclonal
anti-human extracellular TNF-a or monoclonal anti-human
TACE. Cells were then washed in CMF-HBSS supplemented
with 0.5% FBS, centrifuged at 500 g for 1 minute and fixed in
500 ml of CellFixH (Becton Dickinson). The samples were analyzed
by capillary flow cytometry.
Flow cytometry analysis
All samples were run on Guava EasyCyte Plus System (Merck
Millipore, Life Science division, Merck KgaA, Darmstadt,
Germany) equipped with a 488 nm excitation laser and four
emission filters at 530/40, 585/42, 675/30 and 780/30 nm.
Samples were analyzed using Guava ExpressPro software (Merck
Millipore Guava Tech). A dot plot gate was used on forward and
side scatter to eliminate debris. Granulation, size and fluorescence
intensity were recorder for 5,000 cells per analysis.
Image acquisition by confocal microscopy
The stained cells were washed in CMF-HBSS, then incubated
with 7-AAD for 15 minutes in ice. Following one washing step, the
cells were finally resuspended in CMF-HBSS supplemented with
0.5% FBS for slide preparation. To mount cells on slide,
VectashieldHHard SetTM Mounting medium was used. Image
acquisition was made using an inverted confocal microscope Leica
SP5 (Leica Microsystems GmBh) and the acquisition software
Leica LAS AF. The numerical recording of the images and it
analysis was carried out with ImageJ, a freeware created by Wayne
Rasband (NIH, USA).
Fluorometric assay for protease activity on living cells
Protease activity measurements were performed by continuous
monitoring of Fluorescence Resonance Energy Transfer (FRET)
substrates cleavage that is real-time increases in fluorescence
intensity. Two FRET substrates (Peptides International, USA)
were use: MOCAc-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2
(MOCA, substrate for MMPs, Cathepsin D and E, ADAM10 and
ADAM17/TACE, cleaved at the Gly-Leu scissile bound) and Abz-
Leu-Ala-Gln-Ala-Val-Arg-Ser-Ser-Ser-Arg-Dap(Dnp)-NH2 (ABZ,
substrate for TACE, corresponding to the human pro-TNF-a
sequence surrounding the TACE specific cleavage site (Ala-Val
bound)). The fluorescent signals were measured using cuvette-
based spectrofluorometer DeltaRam, computed on the FeliX32
Fluorescence Analysis software 1.1 (Photon Technology Interna-
tional), at lex/lem: 325/400 for MOCA and 320/420 for ABZ.
Prior to the fluorimetric assay, non activated cells were washed
in CMF-HBSS and then resuspended in the same buffer to a final
concentration of 56105 cells/ml. Cell viability was determined
using GuavaHViaCount, and routinely obtained viability was more
than 95%. Cells were dispensed into a plastic (UV compatible) 1-
cm cuvette. For inhibitor studies, tested compound, dissolved in
DMSO, or DMSO alone (control samples) were added to the cells
prior to addition of substrate. Finally, MOCA or ABZ substrate
was dispensed directly into the cuvette at a final concentration of
5 mM and fluorescence measurements were initiated. The final
volume of the samples was always 1.5 ml and final DMSO
concentration never exceeded 0.1%. All assays were carried out
under agitation at room temperature. Cleavage of the substrate
was monitored continuously for 600 s for each experimental point.
The initial velocities (Vo) of the substrates hydrolysis were
determined from the linear section of the fluorescence curves.
Recombinant human TACE enzymatic activities
Recombinant human TACE protein corresponding to the
secreted mature form of TACE with N-terminal sequence
RADPDPMKNT, was obtained from R&D Systems Europe.
Prior to fluorescence measurements, rhTACE was diluted in
1.5 ml of assay buffer (25 mM Tris, pH 9, 2.5 mM ZnCl2 and
0.005% Brij) to a final concentration of 100 ng/ml. The
enzymatic reaction was initiated by addition of MOCA substrate
to a final concentration of 5 mM. The tested compounds, dissolved
in DMSO, or DMSO alone (control samples) were then added
directly into the reaction solution every 600 s. The final titrated
concentrations of the compounds ranged from 0.01 to 100 mM. All
fluorescence measurements were carried out under agitation in 1-
cm quartz cuvette at room temperature. The initial velocities (Vo)
of the substrate hydrolysis were determined from the linear section
of the fluorescence curves.
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Statistical analysis
All statistical analyses were computed with GraphPad PRISMH
(Version 4.0 Software Inc., San Diego CA). Results are given as
mean 6 SD (standard deviation) from ‘‘n’’ independent
experiments. The half-maximal inhibition values (IC50) for each
tested compounds is determined by fitting the data to the sigmoid
dose-response equation:
Y~Bottomz(Top{Bottom)=(1z10 ^ ((logIC50{X )))
where X is the logarithm of the compound’s concentration, Y the
biological response, Bottom the baseline response and Top is the
maximum response.
Comparison analyses are performed using paired Student’s t-
test or Mann-Whitney non-parametric test. Statistical significance
is accepted for a value of p,0.05. For enzymatic analysis, initial
velocities (V0) are computed from the linear section of the
fluorescence curves of substrate hydrolysis using linear regression
analysis. Km (Michaelis Menten constant) and Vmax (the
maximum enzyme velocity of substrate hydrolysis) values are
obtained by fitting the data to equation:
V~Vmax½S=½SzKm
where S is the substrate concentration and V is the enzyme
velocity of substrate hydrolysis.
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